Episode 22 – The tumour microenvironment in immuno-oncology
Tune into this podcast to hear experts discussing the tumour microenvironment in immuno-oncology!
A new episode of our podcast: The tumour microenvironment in immuno-oncology: key themes, Emerging technologies, and future challenges, is now live! Sponsored by Molecular Devices, we will be discussing the hot topic that is tumour microenvironment in immuno-oncology. We will be covering the key themes of the tumour cells interacting with immune cells and these factors that can affect tumour fate and progression.
This conversation features Dr Anuradha Tarafdar, Principal Scientist at Cancer Research Horizons and Michael Klichinsky, Co-Inventor of the CAR-Macrophage technology and a scientific Co-Founder of Carisma Therapeutics.
Key learning points:
- What are the key components of the tumour microenvironment?
- How does the TME cells interact with immune cells?
- Are there any emerging technologies or techniques that show promise in better understanding the complexities of the tumour microenvironment?
Mike is a co-inventor of the CAR-Macrophage technology and a scientific co-founder of Carisma Therapeutics Inc. In his role as Chief Scientific Officer, he oversees the research & discovery efforts of the company.
Mike developed CAR-Macrophages during his doctoral thesis under the co-mentorship of Saar Gill and Carl June at the University of Pennsylvania. Michael’s scientific expertise is in the intersection of immunology, synthetic biology, cancer immunotherapy, and translational pharmacology. Mike previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, and a PhD in Pharmacology from the University of Pennsylvania
Dr Anuradha Tarafdar
Ana is a Principal Scientist at Cancer Research Horizons, and her work is focussed on understanding the pathobiology of tumor cells, the various cells of the tumor microenvironment and their interactions with immune cells. She has over 15 years of research experience in understanding complex human diseases and identifying new therapeutic targets, with experience in both in vitro and in vivo disease models.